Price
$0.7269
Decreased by -3.08%
Dollar Volume
102.37 K
ADR%
7.72
Earnings Report Date (estimate)
Oct 28, 22 (-0.19)
Market Cap.
50.70 M
Shares Float
63.09 M
Shares Outstanding
69.74 M
Beta
1.63
Price / Earnings
-1.35
BPR
259.03
20D Range
0.60 0.80
50D Range
0.35 0.80
200D Range
0.34 0.99
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Oct 28, 22 -0.16
Decreased by -128.57%
-0.19
Increased by +15.79%
Aug 12, 22 -0.19
Decreased by -46.15%
-0.20
Increased by +5.00%
Mar 25, 22 -0.16
Decreased by -6.67%
-0.14
Decreased by -14.29%
Oct 26, 21 -0.12
Decreased by -20.00%
-0.13
Increased by +7.69%
Aug 6, 21 -0.07
Increased by +30.00%
-0.11
Increased by +36.36%
May 11, 21 -0.13
Decreased by -30.00%
-0.11
Decreased by -18.18%
Apr 22, 21 -0.15
Increased by +83.33%
-0.10
Decreased by -50.00%
Nov 9, 20 -0.10
Increased by +33.33%
-0.09
Decreased by -11.11%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-10.93 M
Decreased by -235.15%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-13.03 M
Decreased by -229.23%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-8.55 M
Decreased by -64.98%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-5.43 M
Increased by +31.55%
Decreased by N/A%
Decreased by N/A%
Sep 30, 20 0.00
Decreased by N/A%
-3.26 M
Increased by +70.94%
Decreased by N/A%
Decreased by N/A%
Jun 30, 20 0.00
Decreased by N/A%
-3.96 M
Increased by +63.33%
Decreased by N/A%
Decreased by N/A%
Sep 30, 19 0.00
Decreased by N/A%
-5.19 M
Increased by +34.53%
Decreased by N/A%
Decreased by N/A%
Jun 30, 19 0.00
Decreased by N/A%
-7.93 M
Increased by +13.77%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.